An entry point to the field of neurogenetics — how inherited and de novo genetic variants cause neurological disease, the spectrum of neurogenetic disorders, and the clinical framework for evaluating a patient with a suspected genetic neurological condition.
Tags: Neurogenetics · Basic Genetics
Neurogenetics is the study of how genetic variation — inherited or arising de novo — contributes to neurological disease. As a clinical discipline it bridges neurology and medical genetics, encompassing diagnosis, genetic counseling, and an increasingly robust landscape of mechanism-targeted therapies. The importance of neurogenetics has grown dramatically with next-generation sequencing: roughly 50% of pediatric-onset epilepsies, 30–40% of childhood intellectual disabilities, and a significant fraction of early-onset movement disorders and neurodegenerative diseases now have identifiable genetic causes.
Key Points
Neurological diseases span a continuum of genetic architecture: from fully penetrant Mendelian single-gene disorders to complex polygenic traits modulated by environmental exposures. Understanding which architecture applies to a given condition guides testing strategy, interpretation, and counseling. Most severe early-onset neurological conditions have a monogenic basis; common late-onset conditions (Alzheimer disease, Parkinson disease) are predominantly polygenic with rare high-penetrance variants in a subset of patients.
Key Points
Neurogenetic diseases are conventionally grouped by clinical phenotype, although a single gene can cause entirely distinct diseases (pleiotropy — e.g., CACNA1A causes episodic ataxia type 2, familial hemiplegic migraine, and SCA6) and the same phenotype can result from variants in many genes (genetic heterogeneity). Knowing the most common neurogenetic disease categories and their prototypical genes equips clinicians to build focused differential diagnoses.
Key Points
The genetic evaluation begins with a structured history and examination tailored to identify patterns suggestive of an inherited or de novo neurological disorder. A three-generation pedigree is the cornerstone of genetic assessment and can often reveal the mode of inheritance before any test is ordered. Distinctive features, multi-system involvement, and characteristic neuroimaging patterns guide both the differential diagnosis and the choice of genetic test.
Key Points
The choice of genetic test should be guided by the clinical phenotype, suspected genetic architecture, and available resources. Modern sequencing has shifted practice toward comprehensive 'first-line' tests (chromosomal microarray, exome sequencing) in many settings, while targeted tests remain appropriate when the differential is narrow. Understanding test capabilities and limitations is essential for ordering the right test and interpreting results.
Key Points
1. A 5-year-old child with intellectual disability, autism features, and normal chromosomal microarray undergoes exome sequencing, which reveals a pathogenic variant in SHANK3. The parents are unaffected and do not carry the variant. This variant is best classified as:
A pathogenic variant present in the child but confirmed absent in both biological parents is a de novo variant. De novo variants arise spontaneously during gametogenesis or early embryogenesis and are disproportionately responsible for severe early-onset neurodevelopmental conditions, including intellectual disability and autism. SHANK3 variants (Phelan-McDermid syndrome) are a well-established cause of autism with intellectual disability.
2. A 2-year-old presents with seizures, white matter abnormality on MRI, and progressive neurological decline. Multiple siblings are unaffected, and the parents are first cousins. Which genetic architecture is most likely?
Consanguinity (parents sharing a common ancestor) substantially increases the probability that offspring are homozygous for rare recessive alleles. In a child with progressive neurological disease born to consanguineous parents, autosomal recessive inheritance is the most likely genetic architecture. Many leukodystrophies and neurometabolic disorders follow this pattern. The horizontal pedigree pattern (affected siblings, unaffected parents) further supports AR inheritance.
3. An infant with infantile spasms has a brain MRI showing cortical tubers and subependymal giant cell astrocytomas. An mTOR inhibitor (everolimus) is being considered. The underlying genetic condition is:
Cortical tubers and subependymal giant cell astrocytomas (SEGAs) are hallmarks of tuberous sclerosis complex (TSC), caused by loss-of-function variants in TSC1 or TSC2. These genes encode negative regulators of mTOR signaling — loss of function leads to constitutive mTOR activation and hamartoma formation. Everolimus (an mTOR inhibitor) is FDA-approved for TSC-associated SEGAs and renal angiomyolipomas, representing a prime example of targeted therapy in neurogenetics.
4. A neurologist is evaluating a child with developmental delay and notices café-au-lait macules, axillary freckling, and Lisch nodules on slit lamp exam. The pedigree shows the father has the same findings. This pattern of inheritance is most consistent with:
Vertical transmission (affected individuals in multiple successive generations) is the hallmark of autosomal dominant inheritance. The clinical findings described — café-au-lait macules, axillary freckling, and Lisch nodules — are diagnostic for neurofibromatosis type 1 (NF1), which follows autosomal dominant inheritance with nearly complete penetrance. An affected father transmitting to a child of either sex is consistent with autosomal dominant (not X-linked, where an affected father transmits the X only to daughters).
5. You are counseling a family with a child with unexplained intellectual disability after a negative chromosomal microarray. They ask about the most comprehensive genetic testing option available. Which test detects single nucleotide variants, small insertions/deletions, AND copy number variants in a single assay?
Genome sequencing (GS) interrogates both coding and non-coding regions of the genome, detecting single nucleotide variants (SNVs), small insertions/deletions, copy number variants (CNVs), and structural variants in a single assay. It may also screen for some short tandem repeat expansions. CMA detects CNVs but not SNVs. Trinucleotide repeat PCR is targeted to specific loci. GS is increasingly used as a first-line test in pediatric neurology due to its comprehensive scope.